Realization for regenerative therapy of middle ear mucosa by using autologous nasal mucosal epithelial cell sheets

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1090220316

Enrollment

Registered

2017-11-30

Start date

2017-05-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Middle ear cholesteatoma, Adhesive otitis media

Interventions

Intervention type: Name of intervention:Transplantation of autologous nasal mucosal epithelial cell sheet Dose form / Japanese Medical Device Nomenclature:NOT APPLICABLE Route of administration / Site

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with middle ear cholesteatoma or adhesive otitis media requiring tympanoplasty.

Exclusion criteria

Exclusion criteria: -Patients with critical illness as immunity deficiency, heart disease, renal disease, lever disease, diabetes mellitus, asthma, malignant tumor, etc. -Patients with infectious disease as HBV, HCV, HIV, HTLV, FTA-ABS. -pregnant women, women suspected of being pregnant, and nursing women. -Patient with some complications (Doctor's judgment).

Design outcomes

Primary

Measure	Time frame
-Recurrence rate -Auditory activity -Assessment of computed tomography (CT)	—

Secondary

Measure	Time frame
A multicenter study including transportation.	—

Countries

Japan

Contacts

Public ContactKazuhisa Yamamoto

Jikei University School of Medicine

kazu1109@jikei.ac.jp+81-3-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026